The innate immune response is the first line of defense in the body's recognition of foreign molecules and, as such, plays an active role in the detection of microbial pathogens. In response, microbial pathogens have evolved intricate means to disarm this response. For example, many Gram-negative bacterial pathogens utilize specialized type 3 secretion systems to deliver tens of bacterial proteins directly into host cells proteins. These proteins, which are referred to as effectors, usurp host cell processes to promote bacterial survival. A common emerging theme is that many effectors suppress the production of pro-inflammatory cytokines by inhibiting steps in signaling pathways that lead to activation of NF-?B, a central innate immune response transcription factor. The majority of the anti-inflammatory effectors characterized to date are found in enteric pathogens, including Salmonella, Shigella, Yersinia and enteropathogenic E. coli species, bacterial, which are constantly interfacing with a variety of cell types in the gastrointestinal tract. Dysregulation ofthe innate immune system is linked to many inflammatory autoimmune-based diseases, including inflammatory bowel disease, psoriasis and rheumatoid arthritis. A major advance in the treatment of these diseases has been the development of therapeutics including TNF? inhibitors, humanized antibodies that block activity of this proinflammatory cytokine (i.e., infliximab). However, these agents, like most therapeutic modalities, are delivered systemically, which, in the case of TNF? antagonists, results in systemic immunosuppression increasing the incidence of severe infections, including tuberculosis reactivation and brain abscesses, diseases which could be prevented by targeting immunosuppression to sites of disease. Interestingly, although many gram-negative pathogens, particularly those that target the gastrointestinal tract, use specialized secretion systems to deliver proteins directly into host cells, no commensal organism of mammals has yet been identified to encode such a system. The long-term goal of this project is to develop commensal bacteria that are capable of type 3 secretion and to genetically engineer these bacteria to deliver bacterial effector proteins which specifically inhibit NF-?B activation. It is envisioned that these bacteria could be given to patients as a new means to treat inflammatory bowel disease where immunosuppression is limited to the intestines.

Public Health Relevance

The goal of this work is to develop commensal bacteria as a protein delivery system for the injection of therapeutic defined proteins directly into mammalian cells located in the gastrointestinal tract. Specifically, we propose to develop bacteria that down regulate inflammation in order to reduce the symptoms and disease course associated with inflammatory bowel disease. This therapeutic paradigm has the potential to treat a variety of autoimmune-based diseases and as such would be very valuable towards improving public health.

Agency
National Institute of Health (NIH)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21AI103882-02
Application #
8719017
Study Section
Gastrointestinal Mucosal Pathobiology Study Section (GMPB)
Program Officer
Rothermel, Annette L
Project Start
Project End
Budget Start
Budget End
Support Year
2
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02199